Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma

Pediatr Blood Cancer. 2020 Apr;67(4):e28167. doi: 10.1002/pbc.28167. Epub 2020 Jan 11.

Abstract

We describe 12 pediatric patients (8-16 years) with primary refractory (N = 6) or first relapse (N = 6) Hodgkin lymphoma (HL) treated with ifosfamide, gemcitabine, and vinorelbine (IGEV). The overall response rate to IGEV was 100%, with seven (58%) complete responses (CR) and five (42%) partial responses. Successful CD34+ stem cell mobilization was achieved in all patients. Following subsequent autologous stem cell transplantation, 10 patients (83%) achieved CR. At a median follow-up of 71 months, 11 patients had no evidence of disease. Five-year second event-free survival and overall survival were 83% ± 11.0% and 90.0% ± 9.5%, respectively. IGEV is an effective salvage regimen for children with relapsed/refractory HL.

Keywords: Hodgkin lymphoma; IGEV; autologous stem cell transplantation; pediatric.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Autografts
  • Child
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Disease-Free Survival
  • Female
  • Gemcitabine
  • Hematopoietic Stem Cell Mobilization*
  • Hodgkin Disease* / mortality
  • Hodgkin Disease* / therapy
  • Humans
  • Ifosfamide / administration & dosage
  • Male
  • Salvage Therapy*
  • Stem Cell Transplantation*
  • Survival Rate
  • Vinorelbine / administration & dosage

Substances

  • Deoxycytidine
  • Vinorelbine
  • Ifosfamide
  • Gemcitabine